Items Tagged ‘Chronic Lymphocytic Leukemia’

July 11th, 2016

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

By

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Chronic lymphocytic leukemia is the most common form of adult leukemia. The American […]

View full entry

Tags: 2016, asco, Bruton’s tyrosine kinase, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, CLL, early-stage, ibrutinib, imbruvica, Leukemia, News


March 23rd, 2016

FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia

By

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic lymphocytic leukemia (CLL). The approval means that there is, for the first time, a chemotherapy-free option for initial treatment of CLL.1 Chronic lymphocytic […]

View full entry

Tags: chemotherapy-free option, Chronic Lymphocytic Leukemia, CLL, first-line use, ibrutinib, imbruvica, Leukemia, News


December 31st, 2015

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

By

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, all, AML, ASH, blood cancer, CAR T, Chronic Lymphocytic Leukemia, CLL, fda, Leukemia, Lymphoma


December 17th, 2015

ACP-196 Bruton’s Tyrosine Kinase Inhibitor Safe and Effective for Chronic Lymphocytic Leukemia

By

Clinical results published in the New England Journal of Medicine show that the new drug acalabrutinib (ACP-196) is well tolerated and yields high response rates that are durable in patients with chronic lymphocytic leukemia (CLL). CLL is characterized by the production of atypical lymphocytes. Lymphocytes are specialized immune cells that exist in two forms: B- […]

View full entry

Tags: Acalabrutinib, ACP-196, Chronic, Chronic Lymphocytic Leukemia, CLL, Leukemia, News


November 18th, 2015

Zydelig® Combined with Treanda and Rituxan Appears Promising in Treatment of Chronic Lymphocytic Leukemia

By

Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc today announced that its Phase 3 clinical study evaluating Zydelig® (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a benefit in patients receiving […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, News, Phase III clinical trial, rituxan, Treanda, zydelig


January 15th, 2015

FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Application with New Data in Previously Untreated Chronic Lymphocytic Leukemia

By

Genentech announced that the U.S. Food and Drug Administration (FDA) approved a supplemental biologics license application (sBLA) for Gazyva in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia (CLL). Gazyva was the first medicine approved with the FDA’s Breakthrough Therapy Designation, and was approved for use in combination with chlorambucil in […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, gayza, Leukemia, News, obinutuzumab


September 10th, 2014

Promising Activity of Imbruvica Plus Rituxan in High-Risk CLL

By

Researchers from MD Anderson Cancer Center recently reported in the journal The Lancet Oncology that the combination of Imbruvica® (ibrutinib) and Rituxan® (rituximab) showed promising activity in the management of patients with high-risk chronic lymphocytic leukemia (CLL). CLL is characterized by the production of atypical lymphocytes. Lymphocytes are specialized immune cells that exist in two forms: B- and […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, ibrutinib, imbruvica, Leukemia, News


July 21st, 2014

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment

By

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood cells from a patient and modifying them before infusion back into the patient, is currently involved in a phase […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cd19, Chronic Lymphocytic Leukemia, CLL, Indolent/Low Grade Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, News, Non-Hodgkin's Lymphoma


June 19th, 2014

Imbruvica Found to Extend Survival in CLL Patients

By

Researchers reported at the annual American Society of Clinical Oncology meeting in Chicago that chronic lymphoid leukemia (CLL) patients treated with Imbruvica™ (ibrutinib) showed improved survival when compared to those treated with Arzerra® (ofatumumab). Because the Imbruvica group showed a significant advantage in progression-free survival at an interim point, the trial was halted and Arzerra […]

View full entry

Tags: arzerra, asco, Chronic Lymphocytic Leukemia, CLL, ibrutinib, imbruvica, Leukemia, News


April 30th, 2014

Arzerra Plus Chlorambucil Approved for Previously Untreated CLL

By

The U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab) in combination with chlorambucil in previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate. Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. The American Cancer […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Leukemia, News


February 12th, 2014

Ibrutinib approved by FDA for Chronic Lymphocytic Leukemia

By

On February 12, 2014, the U. S. Food and Drug Administration granted accelerated approval to ibrutinib (IMBRUVICA, Pharmacyclics, Inc.) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.  Ibrutinib previously received accelerated approval on November 13, 2013 for the treatment of patients with mantle cell lymphoma […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Leukemia, News


January 29th, 2014

Chronic Lymphocytic Leukemia Phase III Trial Stopped After Data Shows Clear Advantage for Imbruvica

By

An Independent Data Monitoring Committee (IDMC) recommended that a phase 3 study be stopped early after data indicated that Imbruvica™ (ibrutinib) provided a clear survival advantage compared with the control drug in patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. The American Cancer Society estimates that […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Leukemia, News


November 22nd, 2013

Gazyva Approved for CLL

By

The U.S. Food and Drug Administration (FDA) has approved Gazyva™ (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia. The American Cancer Society estimates that approximately 15,000 people will be diagnosed and 4,580 will die […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Info Type, Leukemia, News


July 18th, 2013

Ibrutinib Highly Active in Patients with Chronic Lymphocytic Leukemia with 17p Deletion

By

The targeted agent ibrutinib produced rapid and durable control of disease in both treatment-naïve and relapsed/refractory patients with 17p deletion chronic lymphocytic leukemia, according to the results of a study presented at the 12th International Conference on Malignant Lymphoma held June 19-22, 2013 in Lugano, Switzerland. Chronic lymphocytic leukemia (CLL) is the most common form of […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Leukemia, News


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma